Physician profile
Robert C Kaiser
NPI 1255362000
$1,137.19
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $191 · 2022: $96.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $217.83 | 2019-2022 | |
| Ethicon US, LLC | $123.44 | 2019 | |
| Janssen Biotech, INC. | $111.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.58 | 2019-2022 | |
| Gilead Sciences, INC. | $100.00 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $92.19 | 2019 | |
| Shionogi INC | $81.27 | 2019 | |
| Allergan, INC. | $67.62 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $58.85 | 2019-2020 | |
| Ucb, INC. | $54.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.45 | 2019 | |
| Qol Medical, LLC | $32.27 | 2019 | |
| Boston Scientific Corporation | $24.76 | 2022 | |
| Merck Sharp & Dohme LLC | $17.50 | 2019 | |
| Endogastric Solutions, INC | $16.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$497.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.